Key papers in Surgery
Pofolia’s corpus holds 91 papers from the Surgery subfield (1986–2026). The list below starts with the most cited.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>
European Heart Journal · 2019 · Q1 · SJR 5.00 · FWCI 808.80 · 8,984 citations · Open access
These 2019 ESC/EAS Guidelines provide updated recommendations for managing dyslipidaemias to reduce cardiovascular risk, emphasizing lipid modification.
MIMIC-III, a freely accessible critical care database
Scientific Data · 2016 · Q1 · SJR 1.00 · 8,216 citations · Open access
MIMIC-III is a new, large, freely accessible database containing comprehensive critical care patient data from a single tertiary hospital.
Guidance for conducting systematic scoping reviews
International Journal of Evidence-Based Healthcare · 2015 · FWCI 90.10 · 7,529 citations
This article introduces systematic scoping reviews, a method for mapping the existing research landscape of a topic, particularly when the literature is complex or has not been previously synthesized.
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
Gut · 2012 · Q1 · SJR 8.00 · FWCI 180.78 · 7,050 citations · Open access
A revised Atlanta classification for acute pancreatitis has been established through international consensus, defining the disease in two phases (early and late) and classifying severity into mild, moderate, or severe based on organ failure duration and local complications.
Comprehensive molecular characterization of gastric adenocarcinoma
Nature · 2014 · Q1 · SJR 19.00 · FWCI 343.99 · 6,542 citations · Open access
A molecular classification of gastric cancer into four subtypes (EBV-positive, microsatellite unstable, genomically stable, and chromosomal unstable) has been proposed based on the analysis of 295 primary tumors.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Circulation · 2019 · Q1 · SJR 8.00 · FWCI 706.47 · 6,210 citations · Open access
This document presents the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol, offering updated recommendations for cardiovascular health based on systematic evidence evaluation.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 571.42 · 6,031 citations · Open access
In patients with cardiovascular disease already on statins, adding evolocumab significantly reduced major cardiovascular events by 15% compared to placebo, achieving LDL cholesterol levels as low as 30 mg/dL.
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
New England Journal of Medicine · 2012 · Q1 · SJR 18.00 · FWCI 253.66 · 5,511 citations · Open access
Preoperative chemoradiotherapy followed by surgery significantly improved median overall survival by over 25 months compared to surgery alone for patients with potentially curable esophageal or esophagogastric-junction cancer.
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Case Reports in Oncology · 2015 · Q3 · FWCI 1156.81 · 5,277 citations · Open access
A rare case of early-stage signet-ring cell carcinoma of the colon in a 36-year-old woman was successfully treated with adjuvant capecitabine, leading to an 18-month disease-free survival.
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Atherosclerosis · 2019 · Q1 · SJR 2.00 · FWCI 546.42 · 4,872 citations · Open access
These guidelines update recommendations for managing dyslipidaemias to reduce cardiovascular risk, emphasizing lipid modification strategies.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
New England Journal of Medicine · 2015 · Q1 · SJR 18.00 · FWCI 435.42 · 4,433 citations · Open access
Adding ezetimibe to statin therapy in patients hospitalized for acute coronary syndromes further reduced cardiovascular events by 7% compared to statin monotherapy over a median of 6 years.
Understanding Bland Altman analysis
Biochemia Medica · 2015 · Q2 · FWCI 149.78 · 4,000 citations · Open access
Bland Altman (B&A) analysis offers a superior method for assessing agreement between two quantitative measurements compared to correlation and regression studies.
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
Circulation · 2017 · Q1 · SJR 8.00 · FWCI 232.54 · 3,726 citations
This American Heart Association scientific statement updates guidance for diagnosing and managing Kawasaki disease, a childhood vasculitis that can cause coronary artery aneurysms.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 311.23 · 3,545 citations · Open access
Adding alirocumab to high-intensity statin therapy significantly reduced the risk of recurrent ischemic cardiovascular events by 15% in patients who recently experienced an acute coronary syndrome.
Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017
JAMA Surgery · 2017 · Q1 · SJR 3.00 · FWCI 248.85 · 3,495 citations
New evidence-based recommendations aim to prevent surgical site infections (SSIs), which are increasingly costly and affect complex patients.
Enhanced Recovery After Surgery
JAMA Surgery · 2017 · Q1 · SJR 3.00 · FWCI 233.49 · 3,436 citations
Enhanced Recovery After Surgery (ERAS) is a multimodal, multidisciplinary approach to perioperative care that significantly improves clinical outcomes and reduces costs.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 331.80 · 3,410 citations · Open access
Pembrolizumab significantly extended overall survival by approximately 3 months compared to chemotherapy in patients with advanced urothelial carcinoma progressing after platinum-based treatment.
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
European Heart Journal · 2017 · Q1 · SJR 5.00 · FWCI 229.00 · 3,293 citations · Open access
These 2017 ESC guidelines, developed with the European Society for Vascular Surgery, provide updated evidence-based recommendations for diagnosing and treating peripheral arterial diseases.
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
European Heart Journal · 2016 · Q1 · SJR 5.00 · FWCI 450.09 · 3,192 citations · Open access
These guidelines consolidate and assess current evidence to aid healthcare professionals in choosing optimal management strategies for dyslipidaemia patients, balancing outcomes with the risk-benefit of interventions.
Comprehensive molecular characterization of urothelial bladder carcinoma
Nature · 2014 · Q1 · SJR 19.00 · FWCI 289.45 · 3,067 citations · Open access
A large-scale molecular analysis of 131 urothelial bladder carcinomas identified recurrent mutations in 32 genes, including 9 not previously linked to cancer, and found potential therapeutic targets in 69% of tumors.
Recently added
A randomized controlled trial of brachial plexus block manipulation versus steroid injection in conscious patients for moderate to severe shoulder stiffness
BMC Musculoskeletal Disorders · 2026 · Q2
An Enhanced Recovery After Manipulation (ERAM) protocol, combining brachial plexus block, manipulation, corticosteroid injection, and rehab, significantly improved shoulder function (Constant-Murley score) and range of motion compared to standard corticosteroid injection and rehab in patients with moderate-to-severe shoulder stiffness.
Return to sport (RTS) tests and criteria following an anterior cruciate ligament (ACL) reconstruction (ACLR): a scoping review
The Knee · 2025 · Q1 · FWCI 8.21 · 7 citations
A scoping review of 33 studies (over 6000 participants) found significant variability in return-to-sport (RTS) criteria after ACL reconstruction, with limb symmetry indexes (LSI) for strength and jump performance (often ≥90%) and RTS timing (6-9 months) being common, but assessments of change of direction, agility, and biomechanics were less frequent.
Sport‐specific differences in ACL injury, treatment and return to sports: Football
Knee Surgery Sports Traumatology Arthroscopy · 2025 · Q1 · SJR 1.00 · FWCI 3.32 · 3 citations · Open access
Football players with ACL ruptures show high rates of surgical treatment success and return to sport, but implementation of prevention and rehabilitation strategies remains challenging.
No Difference in Return-to-Sport Rate or Activity Level in People with Anterior Cruciate Ligament (ACL) Injury Managed with ACL Reconstruction or Rehabilitation Alone: A Systematic Review and Meta-Analysis
Sports Medicine · 2025 · Q1 · SJR 4.00 · FWCI 4.92 · 11 citations · Open access
ACL reconstruction did not improve return-to-sport rates or activity levels compared to rehabilitation alone for ACL injuries, according to a systematic review and meta-analysis of 15 studies.
The formal EU‐US Meniscus Rehabilitation 2024 Consensus: An ESSKA‐AOSSM‐AASPT initiative. Part II—Prevention, non‐operative treatment and return to sport
Knee Surgery Sports Traumatology Arthroscopy · 2025 · Q1 · SJR 1.00 · FWCI 17.71 · 16 citations · Open access
An international EU-US consensus involving 67 experts recommends that meniscus injury prevention is achievable via general knee programs and activity modification, non-operative treatment (including physical therapy) is the primary approach for degenerative tears and some acute tears, and return to sport should be criterion- and time-based, evaluated with patient-reported and performance measures.
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app